

1 **Title**

2 **Gut bacterial tyrosine decarboxylase gene abundance associates with disease duration, medication**
3 **exposure, and gastrointestinal symptoms in a longitudinal cohort of Parkinson's disease patients.**

4 **Authors**

5 Sebastiaan P. van Kessel¹, Petri Auvinen², Filip Scheperjans^{3*}, Sahar El Aidy^{1*}

6

7 **Affiliations**

8 ¹ Host-Microbe Metabolic Interactions, Groningen Biomolecular Sciences and Biotechnology Institute
9 (GBB), University of Groningen, Groningen, the Netherlands

10 ² Institute of Biotechnology, DNA Sequencing and Genomics Laboratory, University of Helsinki,
11 Viikinkaari 5D, 00014 Helsinki, Finland

12 ³ Department of Neurology, Helsinki University Hospital, and Clinicum, University of Helsinki,
13 Haartmaninkatu 4, 00290 Helsinki, Finland

14 *shared last author

15 Correspondence Filip Scheperjans and Sahar El Aidy

16

17

18 **Abstract**

19 Gut microbiota influences the clinical response of a wide variety of orally administered drugs. However,
20 the underlying mechanisms by which drug-microbiota interactions occur are still obscure. Previously,
21 we reported that tyrosine decarboxylating (TDC) bacteria may restrict the levels of levodopa reaching
22 the circulation in patients with Parkinson's disease (PD). We observed a significant positive association
23 between disease duration and the abundance of the bacterial *tdc*-gene. The question arises whether
24 increased exposure to anti-PD medication could affect the abundance of bacterial TDC, to ultimately
25 impact drug efficacy. To this end, we investigated the potential association between anti-PD drug
26 exposure and bacterial *tdc*-gene abundance over a time period of two years in a longitudinal cohort of
27 PD patients and healthy controls. Our data reveal significant associations between *tdc*-gene abundance,
28 anti-PD medication, and gastrointestinal symptoms and warrants further research on the effect of anti-
29 PD medication on microbial changes and gastrointestinal-function.

30

31 **Introduction**

32 In recent years, many studies focused on the changes in the microbiota composition in individuals with
33 Parkinson's disease (PD) compared to healthy subjects (extensively covered in several (systematic)
34 reviews (Boertien et al., 2019; van Kessel and El Aidy, 2019a among others). While certain differential
35 abundance alterations were reproduced across multiple studies, variation of results across studies was
36 considerable (Boertien et al., 2019; van Kessel and El Aidy, 2019a).

37 One of the reasons that may explain the inconsistency among these studies, are confounding factors such
38 as anti-PD medications, disease duration, and GI symptoms. Indeed, studies took these factors into
39 account with variable effort. Catechol-O-methyltransferase (COMT) inhibitors, anticholinergic and
40 potentially levodopa/carbidopa were found to have a significant effect on the changes in the microbiota
41 profile (Aho et al., 2019; Hill-Burns et al., 2017; Scheperjans et al., 2015; Weis et al., 2019).

42 Besides medication, GI-dysfunction should be considered when analyzing the altered microbiota in PD
43 patients. Indeed, PD patients usually experience more GI-dysfunction symptoms compared to healthy
44 controls (HC) (Fasano et al., 2015; Kenna et al., 2021) and intestinal transit time can impact microbiota
45 composition (Falony et al., 2016).

46 Moreover, it has been shown that there is an association between anti-PD medications and GI symptoms.
47 For example, anti-PD medications were shown to have associations (corrected for disease duration) with
48 the total GI Symptoms Rating Score, upper GI symptoms and hypoactive GI functions (Kenna et al.,
49 2021). Furthermore, the proportion of the COMT inhibitor usage was significantly higher in patients
50 with an abnormal transit compared to those with normal transit (Khoshbin et al., 2020). However, the
51 statistical analysis in that study could not distinguish whether the levodopa equivalent daily dose
52 (LEDD) or disease duration was the more contributing factor to the slow colon transit (Khoshbin et al.,
53 2020). In addition, *ex vivo* rodent studies and *in vivo* dog and human studies showed an effect of
54 dopamine agonists and/or dopamine (which can originate from levodopa in PD patients) on the gut
55 motility, recently reviewed (van Kessel and El Aidy, 2019b, and citations in there). Gut microbial

56 metabolization of unabsorbed residues of levodopa were also shown to influence ileal-motility *ex vivo*
57 (van Kessel et al., 2020).

58 Recent studies have shown that tyrosine decarboxylating (TDC) bacteria can decarboxylate levodopa
59 into dopamine in the periphery, thereby may restrict the levels of levodopa available for the brain (van
60 Kessel et al., 2019; Maini Rekdal et al., 2019). Potentially, TDC-harboring bacteria could create a
61 vicious-circle, where peripheral dopamine production affects the gut motility, favoring the colonization
62 of (TDC)-bacteria (van Kessel et al., 2019). Additionally, non-levodopa anti-PD medications
63 (Monoaminoxidase inhibitors, COMT inhibitors, and dopamine agonists), which affect the peripheral
64 dopaminergic-balance, may lead to an altered GI-function, potentially leading to an overgrowth of
65 (TDC)-bacteria, ultimately affecting the bioavailability of levodopa. However, levels of TDC-bacteria
66 have not been measured nor were previously correlated with GI symptoms in longitudinal PD cohorts.

67 In this study we focused on measuring fecal *tdc*-gene abundance and its association with anti-PD
68 medication exposure in a 2 year longitudinal cohort consisting of 67 PD and 65 healthy matched
69 subjects, that was used previously for investigating microbiota and PD (Aho et al., 2019; Scheperjans et
70 al., 2015).

71

72 **Material and Methods**

73 **Cohort**

74 The original gender, age and sex matched cohort was recruited for a pilot study in 2015 investigating
75 PD and gut microbiota (Scheperjans et al., 2015). All subjects were invited to a follow-up on average
76 2.25 ± 0.20 years later to investigate temporal stability in the PD microbiota (Aho et al., 2019). The study
77 was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa. All participants
78 gave written informed consent and the study was registered at clinicaltrials.gov (NCT01536769).

79 From the total 165 subjects (77 PD, 88 HC) recruited in the baseline and follow-up studies (Aho et al.,
80 2019; Scheperjans et al., 2015), 13 subjects (6 PD, 7 HC) were excluded because they did not return for
81 the follow-up study, and 20 subjects (4 PD, 16 HC) were excluded because of various other reasons at
82 baseline or follow up. In the control group, 1 subject was excluded for a sibling with PD, 3 subjects for
83 having a common cold, 8 subjects for hyposmia (pre-motor PD symptom), 2 subjects had a recent
84 surgery, 1 subject had no matching sample, and 1 sample was missing. In the PD group, 1 subject was
85 excluded because of recent surgery, 1 subject had a change in diagnosis, 1 subject because of a sampling
86 handling issue, 1 subject because of medical history. In total 33 subjects (10 PD, 23 HC) were excluded,
87 resulting in 132 subjects (67 PD, 65 HC) used in this study.

88 The following parameters were assessed as described in the previous studies (Scheperjans, 2015, Aho,
89 2019): Gastrointestinal symptoms (Wexner constipation score (Agachan et al., 1996), Rome III
90 questionnaire (Longstreth et al., 2006)), disease severity (Unified Parkinson's Disease Rating Scale
91 (UPDRS) (Fahn, S., Elton, R., and Members of the UPDRS Development Committee, 1987), and
92 medication exposure.

93

94 **DNA extraction**

95 Stool sample collection and DNA isolation was performed in a previous study (Aho et al., 2019). Briefly,
96 stool samples were collected by the study subjects into collection tubes with pre-filled DNA stabilizer
97 (PSP Spin Stool DNA Plus Kit, STRATEC Molecular), and stored in the refrigerator until transport (for
98 up to 3 days). After receipt of the samples, they were transferred to -80°C . DNA from both baseline
99 and follow-up samples were extracted with the PSP Spin Stool DNA Plus Kit (STRATEC Molecular).
100 Each extraction batch included one blank sample to assess potential contamination. (Of note, to prevent
101 potential technical differences, DNA from the baseline samples were extracted at the baseline
102 (Scheperjans et al., 2015) and at follow-up study (Aho et al., 2019), thus the baseline samples were
103 thawed twice.)

104 **Determination of *tdc*-gene abundance**

105 The DNA concentration of the samples was directly estimated from the 96-well plates by measuring the
106 (pathlength corrected) absorbance at 260 nm and 320 nm in a multimode reader, the DNA concentration
107 was calculated as followed: $50 \times (\text{sample}^{260-320} - \text{blank}^{260-320})$. Samples that were negative, very low, or
108 very high in concentration were measured with the nanodrop to confirm. All DNA samples were diluted
109 $20\times$ so that the concentration range would fall in a range of 2-25 ng/ μl (median, 13.7 ng/ μL , interquartile
110 range, 6.9 - 21.8 ng/ μl) and 2 μl was used for quantitative PCR (qPCR). qPCR of *tdc* genes was
111 performed using primers Dec5f (5'-CGTTGTTGGTGTGTTGGCACNACNGARGARG-3') and
112 Dec3r (5'-CCGCCAGCAGAATATGGAAYRTANCCCAT-3') targeting a 350 bp region of the *tdc*
113 gene (Torriani et al., 2008). Primers targeting 16S rRNA gene for all bacteria (Fierer et al., 2005),
114 Eub338 (5'-ACTCCTACGGGAGGCAGCAG-3') and Eub518 (5'-ATTACCGCGGCTGCTGG-3')
115 were used as an internal control. All qPCR experiments were performed in a Bio-Rad CFX96 RT-PCR
116 system (Bio-Rad Laboratories, Veenendaal, The Netherlands) with iQ SYBR Green Supermix (170-
117 8882, Bio-Rad) in 10 μL reactions using the manufacturer's protocol. qPCR was performed using the
118 following parameters: 3 min at 95°C ; 15 sec at 95°C , 1 min at 58°C , 40 cycles. A melting curve was
119 determined at the end of each run to verify the specificity of the PCR amplicons. Data analysis was
120 performed using Bio-Rad CFX Manager 3.1 software. Ct[DEC] values were corrected with the internal

121 control (Ct[16s]) and linearized using $2^{-(Ct^{[DEC]} - Ct^{[16s]})}$ based on the $2^{-\Delta\Delta Ct}$ method (Livak and
122 Schmittgen, 2001).

123

124 **Statistics**

125 All statistical tests were performed in IBM SPSS Statistics version 26. The p-value adjustments were
126 performed in R version 4.0.0 using p.adjust (p-values, “fdr”). The qPCR data were tested for outliers
127 per group and timepoint using the ROUT method (Q=0.1%) in GraphPad Prism v7 and the identified
128 outliers were removed. All variables were tested for normality using Kolmogorov-Smirnov and Shapiro-
129 Wilk tests using the Explore function in SPSS. Based on the distribution of the data, the differences
130 were tested using the appropriate statistical tests. The general linear models (GLMs) were performed
131 using the Generalized Linear Models function in SPSS and the main effects were tested using the Wald
132 Chi Square test. Additionally, the variance inflation factor (VIF) was computed to check for potential
133 collinearity between variables.

134

135 **Results**

136 **Clinical variables**

137 Comparing the clinical variables between the longitudinal cohort of PD and HC did not reveal any
138 significant differences in sex, age (at stool collection) and BMI, no systemic antibiotics were used within
139 the last month (**Supplementary Table 1**). The duration of motor and non-motor symptom onset in the
140 PD cohort at baseline was ~8 years (**Supplementary Table 1**). Over time (between baseline and follow-
141 up), the levodopa equivalent daily dose (LEDD) significantly increased by an average of 116 mg (**Table**
142 **1**). On average, the UPDRS I and II scores significantly increased while UPDRS III (at ON-state)
143 significantly decreased over time, respectively (**Supplementary Table 2**). The latter may be explained
144 by the significant LEDD increase over time. The Hoehn & Yahr (at ON-state) score slightly increased
145 over time (**Supplementary Table 2**).

146 **The gut bacterial *tdc*-gene abundance, GI-symptoms, and medication exposure significantly**
147 **increased over time in PD patients.**

148 Recently, it has been shown that TDC-bacteria in the GI-tract interfere with the availability of levodopa
149 medication in animal models and that longer disease duration and exposure to levodopa may further
150 increase the abundance of TDC-bacteria in the gut (van Kessel et al., 2019). Thus, we sought to
151 investigate the changes in the levels of gut bacterial *tdc*-gene abundance over time in the longitudinal
152 PD cohort including the differences between PD patients and matching HC.

153 When comparing PD patients and HC, PD patients tended to have a higher *tdc*-gene abundance
154 ($p=0.057$) at follow-up (**Figure 1 and Table 2**). Correspondingly, the increase in *tdc*-gene abundance
155 over time, was significantly higher in PD patients compared to HC subjects (Wilcoxon-test, $p=9.7E-07$)
156 with a mean increase of 2.6-fold (**Table 1 and Figure 1**). The results indicate that, over time, *tdc*-gene
157 abundance increases more rapidly in PD patients compared to HC subjects.

158 Because the GI transit time also impacts the microbial composition (Falony et al., 2016), including the
159 TDC bacteria, differences in GI-symptoms were assessed at baseline and follow-up. At both time points,
160 the GI symptoms were significantly more severe in PD patients compared to HC subjects (**Table 2**).

161 Only the Wexner scores, but not the Rome III scores, increased significantly over time in PD patients
162 while in HC subjects, the Wexner scores decreased significantly over time (**Table 1**).

163 Although the LEDD increased significantly over time (**Table 1**), no significant increase was observed
164 for any individual drug in PD patients after correction for FDR, possibly due to the changes of the type
165 of medication (**Table 1**). Nonetheless, at baseline, anticholinergic medication use was significantly
166 higher in PD patients compared to HC subjects (**Table 2**). Only in the HC group, a significant decrease
167 in anacidic medication use was observed over time (**Table 1**).

168 **Anti-PD medications and GI symptoms associate with the gut bacterial *tdc*-gene abundance over**
169 **time.**

170 Using general linear models (GLM), the contribution of the difference in anti-PD medication exposure
171 to the difference in *tdc*-gene abundance over time (follow-up – baseline) was assessed (**Table 3**). The
172 model showed that dose changes of entacapone, rasagiline, pramipexole, and ropinirole significantly
173 contributed to the difference in *tdc*-gene abundance over time. Entacapone and the dopamine agonists
174 contributed positively to the difference in *tdc*-gene abundance, while MAOi contributed negatively to
175 the *tdc*-gene abundance over time, respectively.

176 Because the Wexner scores, but not Rome III, significantly increased over time in the PD group (**Table**
177 **1**), this factor was included in the model to correct for its potential contribution to the *tdc*-gene
178 abundance. Remarkably, Wexner total scores significantly contributed negatively to the *tdc*-gene
179 abundance (**Table 3**), suggesting that subjects with less constipation have an increased *tdc*-gene
180 abundance. Correction for Wexner scores showed that the difference in exposure to anti-PD medication,
181 stated above, still contributed to the model except for ropinirole (p=0.107). The results indicate that
182 prolonged exposure of these specific anti-PD medications, excluding levodopa, contributed to *tdc*-gene
183 abundance independent of the changes in GI symptoms measured by Wexner scores.

184 PD patients usually require change in the anti-PD dosage regimen during the disease progression,
185 compared to patients in a steady state of the disease. Thus, we sought to investigate whether the
186 differences in anti-PD dosage regimen between the two groups was the factor contributing to the changes

187 in *tdc*-gene abundance observed above (**Table 3**). To this end, the PD-group was sub-divided into steady
188 (n=35) and progressing (n=12) PD patients as described and performed in Aho *et al.* (Aho et al., 2019).
189 Comparing the mean differences of the medications of the stable and progressing PD patients over time
190 showed that exposure to levodopa and entacapone significantly increased, while pramipexole exposure
191 significantly decreased in the progressing group compared to the steady group (**Table 4**).

192 When comparing the steady PD patients group with the progressed PD patients group (**Table 5**) only
193 entacapone was not associated with *tdc*-gene abundance and rotigotine now significantly contributed to
194 the model (which was not observed in all the PD patients, **Table 3**), however the significance was lost
195 when correcting for Wexner-score.

196 In the progressing PD group, only entacapone contributed significantly to the change in *tdc*-abundance
197 (**Table 5**). Because the variation inflation factor (VIF, which tests if the variance of a variable increases
198 with another) suggested collinearity between the factors in the progressing PD group, DA-agonists and
199 MAO-inhibitors were combined using LED calculation (Tomlinson et al., 2010). Using the combined
200 variables in the GLM, no collinearity was observed anymore, while entacapone still contributed
201 significantly to the *tdc*-gene abundance (**Supplementary Table 3**). These results indicate that the
202 difference in drug exposure over time between stable and progressed PD patients (**Table 4**), reflect their
203 contribution to the *tdc*-gene abundance in the GLMs (**Table 5 and Supplementary Table 3**). In
204 summary these observations show that, likely due to the change in exposure to these specific anti-PD
205 medications, entacapone is the significant factor contributing to the increase in the *tdc*-gene abundance
206 in progressing PD patients, while the other anti-PD medications contribute to the *tdc*-gene abundance in
207 stable PD patients.

208

209

210 Discussion and Conclusion

211 In this study, we have established that gut bacterial *tdc*-gene abundance is significantly increasing over
212 time in PD patients (**Table 1**), in line with previous results, where a significant correlation between the
213 disease duration and the *tdc*-gene abundance was observed (van Kessel et al., 2019). The levels of gut
214 bacterial *tdc*-gene abundance were not significantly different compared to HC at baseline, but close to
215 significant at follow-up (**Table 2**). Accordingly, the increase in *tdc*-gene abundance was 2.6-fold higher
216 in PD than HC, suggesting that that the increased gene abundance occurs more rapidly in PD patients.
217 In this study we did not find a significant correlation between the levodopa dosages and the *tdc*-gene
218 abundance. This discrepancy could be explained by the relative lower proportion of high levodopa
219 dosages in this study. At baseline and follow-up 19.4% (max 900 mg) and 26.9% (max 875 mg) of the
220 PD patients had a dose higher than 400 mg/day respectively, while in the previous study (van Kessel et
221 al., 2019) 60% of the PD patients received a dosage higher than 400 mg/day (max 1100 mg).

222 Using GLMs, we showed that other anti-PD medications than levodopa contributed significantly to the
223 *tdc*-gene abundance. Importantly, all the tested medications (**Table 3**) affect the (peripheral)
224 dopaminergic-system; COMT inhibitors prevent methylation of levodopa, dopamine, and
225 norepinephrine; MAO inhibitors prevent dopamine, and norepinephrine oxidation; and DA-agonists act
226 on dopamine receptors expressed in the gut. Collectively, these medications were recently shown to
227 elicit an effect on the GI symptoms (Kenna et al., 2021). Although GI-dysfunction might be caused by
228 the degeneration of enteric neurons, as observed in PD patients with chronic constipation (Singaram et
229 al., 1995) and reported in a MPTP mouse model for PD (Anderson et al., 2007), additional dopaminergic
230 medication may impact the GI-function even further. Indeed, the Wexner-score, which significantly
231 increased over time in PD patients, did not change the associations between anti-PD medication and *tdc*-
232 gene abundance (except for ropinirole exposure) when considered as a confounder. This potential link
233 between changes in GI symptoms, as measured by Wexner score, and anti PD medications is in
234 agreement with the outcome of a comprehensive meta-analysis showing that PD patients on ropinirole
235 did not have higher risk of constipation compared to placebo, while those on pramipexole had a higher
236 risk of constipation (Kulisevsky and Pagonabarraga, 2010). Unlike the Wexner score, The Rome III

237 (constipation and defecation) score did not change over time in PD patients which may be explained by
238 the fact that Rome III assesses symptoms retrospectively over a 3-month period which may reduce
239 sensitivity to change. The difference observed between the two questionnaires, conforms the need of the
240 development for more sophisticated protocols to detect and investigate GI symptoms in PD patients
241 (Kenna et al., 2021).

242 Notably, only entacapone exposure in progressing PD patients contributed to the fecal *tdc*-abundance.
243 In fact, *Enterococcus* (genus consisting of species harboring TDCs), among others were found to be
244 significantly increased only in PD patients treated with entacapone (Weis et al., 2019). However, in their
245 study, Weis et al. did not report whether the tested PD patients were on medications, such as MAOi or
246 DA-agonists, other than levodopa and/or entacapone (Weis et al., 2019). Here we show that, next to
247 entacapone, other anti-PD medications may affect gut bacterial *tdc*-gene abundance as well (**Table 3**).

248 The major limitation of this study is that we determined the bacterial *tdc*-gene abundance in fecal
249 samples, which might not reflect the *tdc*-gene levels in the small-intestine, the main absorption site of
250 levodopa and other medication. Besides, the presence of these genes do not necessarily reflect the TDC
251 activity.

252 In summary, the present study implies important associations between anti-PD medication and gut
253 bacterial *tdc*-gene abundance. These associations point towards a complex interactions between anti-PD
254 medication, GI symptoms and gut bacterial *tdc*-gene abundance, which warrants for further research.


255

256

257

258

259 **Figures**



260
261 **Figure 1. *tdc*-gene abundance in PD and healthy control subjects.** The *tdc*-gene abundance is
262 depicted for PD patients (PD, red boxes; dark, baseline; light, follow-up) and healthy control subjects
263 (HC, grey boxes; dark, baseline; light, follow-up) for both time points. Nonparametric paired Wilcoxon
264 tests (W) were performed to test for significant increase over time between paired samples (grey lines).
265 Significant outliers were removed using the ROUT method (Q=0.1%). Nonparametric unpaired Mann-
266 Whitney tests (M-W) were performed to test for significant differences between PD and HC at baseline
267 and follow-up. Boxes represent the median with the interquartile range and whiskers the maxima and
268 minima.

269

270 **Table legends (For the actual tables see attached XLSX-file)**

271 **Table 1.** Paired tests between follow-up and baseline samples in PD and HC of *tdc*-gene abundance,
272 gastrointestinal symptoms and medication. Significant test-results are printed in bold.

273 **Table 2.** Independent tests between PD and HC of *tdc*-gene abundance, gastrointestinal symptoms and
274 medication. Significant test-results are printed in bold.

275 **Table 3.** General linear model of the difference *tdc*-gene abundance over time with anti-PD medication
276 and Wexner-score as variables. Significant variable contributions to the model are printed in bold. VIF;
277 Variance Inflation Factor

278 **Table 4.** Independent tests between progressed and stable PD patients of exposure of anti-PD
279 medications over time. Significant test-results are printed in bold.

280 **Table 5.** General linear model of the difference of *tdc*-gene abundance over time with anti-PD
281 medication and Wexner-score as variable in steady PD patients. Significant variable contributions to
282 the model are printed in bold. VIF; Variance Inflation Factor

283 **Table 6.** General linear model of the difference of *tdc*-gene abundance over time with anti-PD
284 medication and Wexner-score as variable in progressing PD patients (with collinearity observed).
285 Significant variable contributions to the model are printed in bold. VIF; Variance Inflation Factor

286 **Supplementary Table 1.** Independent test of the basic variables Sex, Age, and BMI. Significant test-
287 results are printed in bold.

288 **Supplementary Table 2.** Paired tests between follow-up and baseline of LEDD, and UPDRS scores.
289 Significant test-results are printed in bold.

290 **Supplementary Table 3.** General linear model of the difference *tdc*-gene abundance over time with
291 anti-PD medication LEDD combined and Wexner-score as variables in progressing PD patients.

292

293 **Author contributions**

294 SVK performed the qPCR, the statistical analysis, and wrote the original manuscript which was
295 reviewed and modified by PA, FS and SEA. SVK, FS and SEA contributed to interpreting the results
296 and the conceptualization of the study. FS performed the clinical evaluations of subjects and was
297 responsible for the original cohort-data.

298

299 **Acknowledgements and funding**

300 We thank Reeta Levo for her invaluable contribution as research nurse. We thank Ursula Lönnqvist,
301 Pedro Bento Pereira, and Simo Soila for skillful technical assistance in the Helsinki laboratory. We
302 thank Velma Aho for supplying and formatting the clinical metadata for the samples.

303 FS received funding from The Michael J. Fox Foundation for Parkinson's Research, The Finnish
304 Parkinson Foundation, the Academy of Finland (295724, 310835), Helsinki University Hospital
305 (T1010NL101, TYH2018224, TYH2020335), and Hyvinkää Hospital (M6095PEV12).

306

307 **Competing interests**

308 FS has patents issued (FI127671B & US10139408B2) and pending (US16/186,663 & EP3149205) that
309 are assigned to NeuroBiome Ltd. FS is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd.,
310 is a member of the scientific advisory board and has received consulting fees and stock options from
311 Axial Biotherapeutics. FS has received consulting and lecture fees from Orion, Abbvie, Herantis, GE
312 Healthcare, Merck, and Teva. SEA has acquired a research grant from Weston Brain Institute. The
313 funders have no role in the preparation of the manuscript.

314 **Data availability**

315 Clinical data are not publicly available due to participant privacy and are available from
316 the corresponding authors on reasonable request.

317

318 **References**

- 319 Agachan, F., Chen, T., Pfeifer, J., Reissman, P., and Wexner, S.D. (1996). A constipation scoring
320 system to simplify evaluation and management of constipated patients. *Dis. Colon Rectum* 39, 681–
321 685.
- 322 Aho, V.T.E., Pereira, P.A.B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., and Scheperjans,
323 F. (2019). Gut microbiota in Parkinson's disease: Temporal stability and relations to disease
324 progression. *EBioMedicine* 44, 691–707.
- 325 Anderson, G., Noorian, A.R., Taylor, G., Anitha, M., Bernhard, D., Srinivasan, S., and Greene, J.G.
326 (2007). Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP
327 mouse model of Parkinson's disease. *Exp. Neurol.* 207, 4–12.
- 328 Boertien, J.M., Pereira, P.A.B., Aho, V.T.E., and Scheperjans, F. (2019). Increasing Comparability
329 and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review. *J. Parkinsons.*
330 *Dis.* 9, S297–S312.
- 331 Fahn, S., Elton, R., and Members of the UPDRS Development Committee, " (1987). The Unified
332 Parkinson's Disease Rating Scale. In *Recent Developments in Parkinson's Disease*, M. Fahn, S.,
333 Marsden, C.D., Calne, D.B. and Goldstein, ed. (Florham Park: McMellam Health Care Information),
334 pp. 153–163.
- 335 Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder,
336 M.J., Valles-Colomer, M., Vandeputte, D., et al. (2016). Population-level analysis of gut microbiome
337 variation. *Science* 352, 560–564.
- 338 Fasano, A., Visanji, N.P., Liu, L.W.C., Lang, A.E., and Pfeiffer, R.F. (2015). Gastrointestinal
339 dysfunction in Parkinson's disease. *Lancet Neurol.* 14, 625–639.
- 340 Fierer, N., Jackson, J.A., Vilgalys, R., and Jackson, R.B. (2005). Assessment of Soil Microbial
341 Community Structure by Use of Taxon-Specific Quantitative PCR Assays. *Appl. Environ. Microbiol.*
342 71, 4117–4120.

- 343 Hill-Burns, E.M., Debelius, J.W., Morton, J.T., Wissemann, W.T., Lewis, M.R., Wallen, Z.D.,
344 Peddada, S.D., Factor, S.A., Molho, E., Zabetian, C.P., et al. (2017). Parkinson's disease and
345 Parkinson's disease medications have distinct signatures of the gut microbiome. *Mov. Disord.* *32*,
346 739–749.
- 347 Kenna, J.E., Bakeberg, M.C., Gorecki, A.M., Chin Yen Tay, A., Winter, S., Mastaglia, F.L., and
348 Anderton, R.S. (2021). Characterization of Gastrointestinal Symptom Type and Severity in
349 Parkinson's Disease: A Case–Control Study in an Australian Cohort. *Mov. Disord. Clin. Pract.* *8*, 245–
350 253.
- 351 van Kessel, S.P., and El Aidy, S. (2019a). Bacterial Metabolites Mirror Altered Gut Microbiota
352 Composition in Patients with Parkinson's Disease. *J. Parkinsons. Dis.* *9*, S359–S370.
- 353 van Kessel, S.P., and El Aidy, S. (2019b). Contributions of gut bacteria and diet to drug
354 pharmacokinetics in the treatment of Parkinson's disease. *Front. Neurol.* *10*.
- 355 van Kessel, S.P., Frye, A.K., El-Gendy, A.O., Castejon, M., Keshavarzian, A., van Dijk, G., and El
356 Aidy, S. (2019). Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of
357 Parkinson's disease. *Nat. Commun.* *10*, 310.
- 358 van Kessel, S.P., de Jong, H.R., Winkel, S.L., van Leeuwen, S.S., Nelemans, S.A., Permentier, H.,
359 Keshavarzian, A., and El Aidy, S. (2020). Gut bacterial deamination of residual levodopa medication
360 for Parkinson's disease. *BMC Biol.* *18*, 137.
- 361 Khoshbin, K., Hassan, A., and Camilleri, M. (2020). Cohort Study in Parkinsonism: Delayed Transit,
362 Accelerated Gastric Emptying, and Prodromal Dysmotility. *Neurol. Clin. Pract.*
363 10.1212/CPJ.0000000000001003.
- 364 Kulisevsky, J., and Pagonabarraga, J. (2010). Tolerability and Safety of Ropinirole versus Other
365 Dopamine Agonists and Levodopa in the Treatment of Parkinsons Disease: Meta-Analysis of
366 Randomized Controlled Trials. *Drug Saf.* *33*, 147–161.
- 367 Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time

368 quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods* 25, 402–408.

369 Longstreth, G.F., Thompson, W.G., Chey, W.D., Houghton, L.A., Mearin, F., and Spiller, R.C. (2006).
370 Functional Bowel Disorders. *Gastroenterology* 130, 1480–1491.

371 Maini Rekdal, V., Bess, E.N., Bisanz, J.E., Turnbaugh, P.J., and Balskus, E.P. (2019). Discovery and
372 inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. *Science* 364, eaau6323.

373 Scheperjans, F., Aho, V., Pereira, P.A.B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E.,
374 Kaakkola, S., Eerola-Rautio, J., Pohja, M., et al. (2015). Gut microbiota are related to Parkinson’s
375 disease and clinical phenotype. *Mov. Disord.* 30, 350–358.

376 Singaram, C., Ashraf, W., Gaumnitz, E.A., Torbey, C., Sengupta, A., Pfeiffer, R., and Quigley,
377 E.M.M. (1995). Dopaminergic defect of enteric system in Parkinson’s disease patients with chronic
378 constipation. *Lancet* 346, 861–864.

379 Tomlinson, C.L., Stowe, R., Patel, S., Rick, C., Gray, R., and Clarke, C.E. (2010). Systematic review
380 of levodopa dose equivalency reporting in Parkinson’s disease. *Mov. Disord.* 25, 2649–2653.

381 Torriani, S., Gatto, V., Sembeni, S., Tofalo, R., Suzzi, G., Belletti, N., Gardini, F., and Bover-Cid, S.
382 (2008). Rapid detection and quantification of tyrosine decarboxylase gene (tdc) and its expression in
383 gram-positive bacteria associated with fermented foods using PCR-based methods. *J. Food Prot.* 71,
384 93–101.

385 Weis, S., Schwiertz, A., Unger, M.M., Becker, A., Faßbender, K., Ratering, S., Kohl, M., Schnell, S.,
386 Schäfer, K.H., and Egert, M. (2019). Effect of Parkinson’s disease and related medications on the
387 composition of the fecal bacterial microbiota. *Npj Park. Dis.* 5, 1–9.

388

389

Table 1. Paired tests between follow-up and baseline samples in PD and HC of tdc-gene abundance, gastrointestinal symptoms and medication. Significant test-results are printed in bold.

	Paired tests (Follow-up - Baseline)												PD on medication				
	PD						Control						Baseline (%)	Follow up (%)			
	Paired mean difference	Baseline Mean±SD (n)	Follow up Mean±SD (n)	T-test	Wilcoxon	McNemar	FDR	Paired mean difference	Baseline Mean±SD (n)	Follow up Mean±SD (n)	T-test	Wilcoxon			McNemar	FDR	
tdc-gene abundance																	
tdc-gene abundance (outliers removed)	2.2E-06	1.5E-6±1.3E-6 (55)	3.7E-6±2.6E-6 (55)		9.7E-07		na	8.61E-07	2.2E-6±2.2E-6 (54)	3.1E-6±2.7E-6 (54)		0.167		na			
Gastrointestinal symptoms																	
Wexner total score	0.72	5.66±4.01 (67)	6.37±4.63 (67)		0.033		0.059	-0.54	2.92±2.61 (65)	2.38±2.58 (65)		0.010		0.030			
Rome III (constipation and defecation)	-0.01	7.37±5.96 (67)	7.36±5.17 (67)		0.685		0.685	-0.22	2.97±3.60 (65)	2.75±3.60 (65)		0.651		0.977			
Anti-PD medication exposure																	
LEDD (mg)	116.40	444.2±315.6 (66)	560.6±294.0 (66)		1.8E-06		3.1E-05										
Levodopa																	
levodopa IR (mg)	54.10	99.63±159.46 (67)	153.73±204.92 (67)		0.028		0.221									35.8	41.8
duodopa (mg)	19.33	0.00±0.00 (66)	19.33±157.06 (66)		0.317		0.708									0.0	1.5
levodopa CR (mg)	-8.96	47.76±157.98 (67)	38.81±115.41 (67)		1.000		1.000									11.9	14.9
levodopa (with entacapone) (mg)	19.03	88.06±220.17 (67)	107.09±226.33 (67)		0.513		0.872									14.9	22.4
COMT inhibitors																	
entacapone (mg)	49.25	146.27±357.74 (67)	195.52±385.51 (67)		0.319		0.708									14.9	22.4
MAO inhibitors																	
selegiline (mg)	-0.51	4.10±4.84 (67)	3.59±4.74 (67)		0.348		0.708									43.3	38.8
rasagiline (mg)	0.06	0.25±0.44 (67)	0.31±0.47 (67)		0.102		0.434									25.4	31.3
Dopamine agonists																	
rotigotine (mg)	0.42	0.00±0.00 (67)	0.42±1.62 (67)		0.039		0.221									0.0	7.5
pramipexole (mg)	-0.06	0.62±0.82 (67)	0.56±0.88 (67)		0.613		0.885									43.3	38.8
ropinirole (mg)	0.04	3.15±5.18 (67)	3.19±6.02 (67)		0.951		1.000									34.3	29.9
bromocriptine (mg)	n.a.	0.15±1.22 (67)	0.15±1.22 (67)		1.000		1.000									1.5	1.5
Other medication																	
amantadine (mg)	1.49	6.72±40.73 (67)	8.21±38.53 (67)		1.000		1.000									3.0	4.5
biperiden (mg)	-0.11	0.21±0.94 (67)	0.10±0.55 (67)		0.345		0.708									6.0	4.5
exelon (mg)	n.a.	0.00±0.00 (67)	0.00±0.00 (67)		1.000		1.000									0.0	0.0
Use of anacidic (Yes/No)	-3%	6/61 (67)	4/63(67)				0.625	0.885	-11%	7/58 (65)	0/65 (65)		0.016	0.032		9.0	6.0
Use of anticholinergic (Yes/No)	-4%	6/61 (67)	3/64(67)				0.375	0.708	2%	0/65 (65)	1/65 (65)		1.000	1.000		9.0	4.5

Table 2. Independent tests between PD and HC of *tdc*-gene abundance, gastrointestinal symptoms and medication. Significant test-results are printed in bold

	Independent-tests (PD - Control)														
	Baseline						Follow up								
	Mean Difference	PD Mean±SD (n)	Control Mean±SD (n)	T-test	Mann-Whitney	Fisher's test	FDR	Mean Difference	PD Mean±SD (n)	Control Mean±SD (n)	T-test	Mann-Whitney	Fisher's test	FDR	
<i>tdc</i> -gene abundance															
<i>tdc</i> -gene abundance (outliers removed)	-7.4E-07	1.5E-6±1.3E-6 (55)	2.2E-6±2.2E-6 (54)				0.177	na						na	
Gastrointestinal symptoms															
Wexner total score	2.73	5.66±4.01 (67)	2.92±2.61 (65)				2.4E-05	2.4E-05	3.99	6.37±4.63 (67)	2.38±2.58 (65)			5.9E-09	1.2E-08
Rome III (constipation and defecation)	4.40	7.37±5.96 (67)	2.97±3.60 (65)				1.2E-06	2.4E-06	4.60	7.36±5.17 (67)	2.75±3.60 (65)			1.3E-08	1.3E-08
Medication															
Use of anacidic (Yes/No)	-2%	6/61 (67)	7/58(65)				0.777	0.777	6%	4/63 (67)	0/65 (65)			0.119	0.238
Use of anticholinergic (Yes/No)	9%	6/61 (67)	0/65 (65)				0.028	0.056	3%	3/64 (67)	1/64 (65)			0.619	0.619

Table 3. General linear model of the difference *tdc*-gene abundance overtime with anti-PD medication and Wexner-score as variables. Significant variable contributions to the model are printed in bold. VIF; Variance Inflation Factor

All PD patients (n=55)	Difference <i>tdc</i> - gene abundance 2y-0y (no outliers)					
	Not corrected for Wexner score			Corrected for Wexner score		
	β	p-value	VIF	β	p-value	VIF
(Intercept)	2.1E-06	0.000		2.5E-06	0.000	
Difference levodopa sum (mg)	1.0E-09	0.671	1.375	-3.2E-10	0.895	1.466
Difference entacapone (mg)	2.1E-09	0.032	1.163	2.4E-09	0.011	1.189
Difference selegeline (mg)	-9.4E-08	0.258	1.215	-1.0E-07	0.191	1.218
Difference rasagiline (mg)	-2.7E-06	0.035	1.366	-3.0E-06	0.013	1.388
Difference rotigotine (mg)	2.3E-07	0.245	1.161	1.7E-07	0.374	1.184
Difference pramipexole (mg)	2.0E-06	0.001	1.415	1.7E-06	0.005	1.515
Difference ropinirole (mg)	2.2E-07	0.028	1.367	1.6E-07	0.107	1.472
Difference in Wexner total score		Not included		-3.0E-07	0.024	1.265

Table 4. Independent tests between progressed and stable PD patients of exposure of anti-PD medications overtime. Significant test-results are printed in bold.

Independent-tests (Progressed-Stable)						
	Mean Difference	Progressed Mean±SD (n)	Stable Mean±SD (n)	T-test	Mann-Whitney	Fishers's test FDR
Difference levodopa sum (mg)	103.5	208.33±156.43 (12)	104.86±116.32 (36)		0.022	0.051
Difference entacapone (mg)	361.1	366.67±510.50 (12)	5.56±255.17 (36)		0.009	0.051
Difference selegeline (mg)	1.5	0.83±5.15 (12)	-0.68±4.46 (36)		0.737	0.983
Difference rasagiline (mg)	0.0	0.08±0.29 (12)	0.08±0.28 (36)		0.934	0.983
Difference rotigotine (mg)	0.4	0.83±2.89 (12)	0.39±1.34 (36)		0.983	0.983
Difference pramipexole (mg)	-0.4	-0.31±0.65 (12)	0.10±0.58 (36)		0.019	0.051
Difference ropinirole (mg)	-0.3	-0.58±5.53 (12)	-0.28±3.18 (36)		0.785	0.983

Table 5. General linear model of the difference of *tdc*-gene abundance overtime with anti-PD medication and Wexner-score as variable in steady and progressing PD patients. Significant variable contributions to the model are printed in bold. VIF; Variance Inflation Factor

	Stable PD patients (n=36)						Progressed PD patients (n=12)					
	Difference <i>tdc</i> -gene abundance 2y-0y (no outliers)						Difference <i>tdc</i> -gene abundance 2y-0y (no outliers)					
	Not corrected for Wexner score			Corrected for Wexner score			Not corrected for Wexner score			Corrected for Wexner score		
	β	p-value	VIF	β	p-value	VIF	β	p-value	VIF	β	p-value	VIF
(Intercept)	2.1E-06	0.001		2.4E-06	0.000		6.5E-07	0.589		1.3E-06	0.511	
Difference levodopa sum (mg)	3.4E-09	0.436	2.120	2.7E-09	0.506	2.133	7.1E-10	0.868	1.879	-1.2E-09	0.848	4.149
Difference entacapone (mg)	-4.1E-10	0.777	1.164	-2.0E-10	0.884	1.171	5.2E-09	0.000	1.780	4.8E-09	0.002	2.665
Difference selegeline (mg)	-1.8E-07	0.053	1.442	-1.9E-07	0.033	1.445	-2.4E-07	0.163	3.392	-2.6E-07	0.145	3.538
Difference rasagiline (mg)	-3.5E-06	0.006	1.100	-3.8E-06	0.002	1.114	-4.0E-06	0.173	2.998	-3.8E-06	0.190	3.045
Difference rotigotine (mg)	6.1E-07	0.038	1.287	4.5E-07	0.117	1.388	4.8E-07	0.072	2.494	4.3E-07	0.141	3.033
Difference pramipexole (mg)	2.3E-06	0.002	1.496	2.4E-06	0.001	1.502	1.8E-06	0.092	2.152	7.6E-07	0.789	14.750
Difference ropinirole (mg)	5.4E-07	0.000	1.937	4.5E-07	0.003	2.126	1.3E-07	0.296	1.930	4.3E-08	0.857	7.454
Difference in Wexner total score		Not included		-2.8E-07	0.048	1.217		Not included		-2.7E-07	0.680	8.843

Supplementary Table 1. Independent test of the basic variables Sex, Age, and BMI. Significant test-results are printed in bold.

	Independent-tests (PD - Control)						
	Mean Difference	PD Mean±SD (n)	Control Mean±SD (n)	T-test	Mann-Whitney	Fishers's test	FDR
Sex (Female/Male)	0.02%	33/34 (67)	32/33 (65)			1.000	
BMI at baseline (kg/m ²)	0.95	27.2±4.3 (62)	26.2±3.5 (61)	0.181			
BMI at follow up (kg/m ²)	0.71	27.3±4.6 (67)	26.6±3.7 (65)	0.330			
Age at stool collection baseline (years)	0.76	65.4±5.5 (67)	64.6±7.0 (65)	0.486			
Age at stool collection follow up (years)	0.92	67.6±5.5 (66)	66.7±6.9 (64)	0.399			
Age symptom onset							
Age at motor symptoms onset (years)		59.5±5.3 (66)					
Age at non-motor symptoms onset (years)		57.7±7.8 (53)					
Duration of motor symptoms (years)		8.2±4.1 (66)					
Duration of non-motor symptoms (years)		10.0±6.9 (52)					

Supplementary Table 2. Paired tests between follow-up and baseline of LEDD, and UPDRS scores. Significant test-results are printed in bold.

	Paired-tests (Follow-up - Baseline)						
	Mean Difference	Baseline Mean±SD (n)	Follow up Mean±SD (n)	T-test	Wilcoxon	McNemar	FDR
UPDRS I	0.63	1.8±1.8 (67)	2.5±1.8 (67)		0.002		0.003
UPDRS II	1.78	11.6±5.5 (67)	11.6±5.5 (67)		0.001		0.003
UPDRS III (ON-state)	-3.11	31.9±8.9 (64)	28.8±8.7 (64)	0.001			0.003
UPDRS III (OFF-state)		na	33.7±10.6 (65)				
UPDRS IV	0.84	2.2±2.2 (67)	3.1±3.2 (67)		0.008		0.010
H&Y (ON-state)	0.13	2.4±.5 (64)	2.5±0.7 (64)		0.054		0.054
H&Y (OFF-state)		na	2.5±0.8 (64)				

Supplementary Table 3. General linear model of the difference *tdc*-gene abundance overtime with anti-PD medication LEDD combined and Wexner-score as variables in progressing PD patients. □

Progressed PD patients (n=12)	Difference <i>tdc</i> - gene abundance 2y-0y (no outliers)					
	Not corrected for Wexner score			Corrected for Wexner score		
	β	p-value	VIF	β	p-value	VIF
(Intercept)	6.8E-07	0.550		1.5E-06	0.273	
Difference levodopa sum (mg)	-4.8E-10	0.913	1.500	-2.3E-09	0.619	1.783
Difference entacapone (mg)	4.5E-09	0.001	1.414	4.6E-09	0.000	1.421
Difference MAOi LED (mg)	-1.0E-08	0.534	1.315	-9.6E-09	0.547	1.317
Difference in DA agonist LED (mg)	7.1E-09	0.219	2.383	3.2E-09	0.641	3.601
Difference in Wexner total score		Not included		-3.4E-07	0.323	1.874